相关实验视频
Updated: Jan 18, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
19.0K
虚拟现实干预对阿尔茨海默病老年人的生活质量,认知功能和身体功能的有效性:系统审查
Edgar Vásquez-Carrasco1, Jordan Hernandez-Martinez2, María Sepúlveda-Ramírez3
1School of Occupational Therapy, Faculty of Psychology, Universidad de Talca, Talca 3465548, Chile; Centro de Investigación en Ciencias Cognitivas, Faculty of Psychology, Universidad de Talca 3465548, Chile; VITALIS Longevity Center, Universidad de Talca, Talca 3465548, Chile.
Ageing research reviews
|May 28, 2025
概括
虚拟现实 (VR) 干预对阿尔茨海默病 (AD) 的老年人有潜在的益处,改善认知和身体功能. 虽然并不总是显著,但一些研究表明对生活质量有积极影响.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 康复科学 康复科学 康复科学
背景情况:
- 阿尔茨海默病 (AD) 显著影响老年人的生活质量,认知功能和身体能力.
- 越来越多的人对非药物干预措施感兴趣,以管理AD症状并改善患者的治疗结果.
研究的目的:
- 系统地审查和综合关于虚拟现实 (VR) 干预措施对被诊断患有阿尔茨海默病的老年人有效性的科学证据.
- 评估VR对这一群体生活质量,认知功能和身体功能的影响.
主要方法:
- 在七个主要数据库中进行了系统的文献搜索,截至2025年3月.
- 使用PICOS框架分析了7项涉及517名患有AD的老年人研究,使用PRISMA,RoB 2和GRADEpro工具评估了方法质量.
- 由于评估工具的异质性,元分析是不可行的.
主要成果:
- 在所有研究中,VR干预组和对照组之间没有观察到一致的显著差异.
- 然而,个别研究报告了改善:两个表明生活质量和认知功能有所改善,三个显示身体功能更好.
- 干预措施各不相同,包括沉浸式认知训练和运动游戏,持续时间为4至16周.
结论:
- 虚拟现实干预措施在阿尔茨海默病的老年人中改善认知和身体功能方面表现有前途.
- 虚拟现实也可能为生活质量带来好处,尽管证据不太一致.
- 需要使用标准化的方法进行进一步的研究,以确认VR在AD管理中的有效性.
更多相关视频
相关概念视频
01:30Cognitive Development During Adulthood
792
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
792
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
190
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
190
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K